Nabriva Therapeutics (STU:NTY) Pretax Margin % : -468.56% (As of Jun. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Nabriva Therapeutics Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Nabriva Therapeutics's Pre-Tax Income for the three months ended in Jun. 2023 was €-11.13 Mil. Nabriva Therapeutics's Revenue for the three months ended in Jun. 2023 was €2.38 Mil. Therefore, Nabriva Therapeutics's pretax margin for the quarter that ended in Jun. 2023 was -468.56%.

The historical rank and industry rank for Nabriva Therapeutics's Pretax Margin % or its related term are showing as below:

STU:NTY' s Pretax Margin % Range Over the Past 10 Years
Min: -2421.26 Med: -1066.89 Max: -155.93
Current: -184.52

STU:NTY's Pretax Margin % is ranked worse than
51.76% of 1020 companies
in the Biotechnology industry
Industry Median: -154.275 vs STU:NTY: -184.52

Nabriva Therapeutics Pretax Margin % Historical Data

The historical data trend for Nabriva Therapeutics's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nabriva Therapeutics Pretax Margin % Chart

Nabriva Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Pretax Margin %

Get a 7-Day Free Trial

-1,765.25

-1,066.93

-2,421.50

-179.90

-155.93

Nabriva Therapeutics Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Pretax Margin %	Get a 7-Day Free Trial															-121.80	-125.16	-215.25	-114.63	-468.56

Competitive Comparison of Nabriva Therapeutics's Pretax Margin %

For the Biotechnology subindustry, Nabriva Therapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nabriva Therapeutics's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nabriva Therapeutics's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Nabriva Therapeutics's Pretax Margin % falls into.

Nabriva Therapeutics Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Nabriva Therapeutics's Pretax Margin for the fiscal year that ended in Dec. 2022 is calculated as

Pretax Margin	=	Pre-Tax Income (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-52.502	/	33.671
	=	-155.93 %

Nabriva Therapeutics's Pretax Margin for the quarter that ended in Jun. 2023 is calculated as

Pretax Margin	=	Pre-Tax Income (Q: Jun. 2023 )	/	Revenue (Q: Jun. 2023 )
	=	-11.133	/	2.376
	=	-468.56 %

Nabriva Therapeutics (STU:NTY) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.

Nabriva Therapeutics Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Nabriva Therapeutics's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Nabriva Therapeutics (STU:NTY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nabriva Therapeutics PLC (STU:NTY) » Definitions » Pretax Margin %

Comparable Companies

Traded in Other Exchanges

NBRVF:USA

Address

Alexandra House, Office 225/227, The Sweepstakes, Dublin, IRL, 4

Website

https://www.nabriva.com

Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company has developed a product candidate, XENLETA, a semi-synthetic pleuromutilin antibiotic that is the first in its class for oral and IV administration in humans. XENLETA is designed to inhibit the synthesis of a specific protein on the bacterial ribosome. It operates in one reportable segment, which comprises the research and development of novel anti-infective agents to treat serious infections. The firm has commercial rights to two approved products, SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO.

Nabriva Therapeutics (STU:NTY) Headlines

No Headlines